BC Week In Review | Jan 5, 2015
Clinical News

AV4025: Phase Ib data

A double-blind, placebo-controlled, Russian Phase Ib trial in 15 treatment-naïve patients with HCV genotype 1b infection showed that once-daily 20 and 40 mg doses of oral AV-4025 for 3 days were well tolerated with no...
BC Week In Review | May 19, 2014
Clinical News

AV4025: Phase Ib started

AllaChem began a double-blind, placebo-controlled, Russian Phase Ib trial to evaluate 20 or 40 mg oral AV4025 once daily for 3 days in about 20 treatment-naïve patients with HCV infection. AllaChem LLC , Hallandale Beach, Fla....
BC Week In Review | Oct 21, 2013
Clinical News

AV4025: Phase I data

AllaChem LLC , Hallandale Beach, Fla.   Product: AV4025   Business: Infectious   Molecular target: HCV NS5A protein   Description: HCV NS5A inhibitor   Indication: Treat chronic HCV infection   Endpoint: Safety and pharmacokinetics   Status:...
BC Week In Review | Aug 19, 2013
Clinical News

AV4025: Phase I started

Alla Chem LLC , Hallandale Beach, Fla.   Product: AV4025   Business: Infectious   Molecular target: HCV NS5A protein   Description: HCV NS5A inhibitor   Indication: Treat chronic HCV infection   Endpoint: Safety and pharmacokinetics  ...
Items per page:
1 - 4 of 4